KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Accumulated Expenses (2018 - 2023)

Esperion Therapeutics (ESPR) has disclosed Other Accumulated Expenses for 6 consecutive years, with $25.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Other Accumulated Expenses rose 89.32% year-over-year to $25.0 million, compared with a TTM value of $25.0 million through Dec 2023, up 89.32%, and an annual FY2023 reading of $25.0 million, up 89.32% over the prior year.
  • Other Accumulated Expenses was $25.0 million for Q4 2023 at Esperion Therapeutics, up from $13.2 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $30.4 million in Q4 2021 and bottomed at $3.2 million in Q1 2020.
  • Average Other Accumulated Expenses over 5 years is $13.0 million, with a median of $10.9 million recorded in 2019.
  • The sharpest move saw Other Accumulated Expenses soared 3910.47% in 2019, then tumbled 56.58% in 2022.
  • Year by year, Other Accumulated Expenses stood at $11.9 million in 2019, then surged by 108.83% to $24.8 million in 2020, then rose by 22.67% to $30.4 million in 2021, then crashed by 56.58% to $13.2 million in 2022, then soared by 89.32% to $25.0 million in 2023.
  • Business Quant data shows Other Accumulated Expenses for ESPR at $25.0 million in Q4 2023, $13.2 million in Q4 2022, and $30.4 million in Q4 2021.